An Early Phase 1 interventional study of Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101) and Vancomycin and neomycin antibiotic pretreatment in Kidney Stones, Urinary Stone Disease / Nephrolithiasis and Recurrent Calcium-oxalate Kidney Stones, sponsored by Joshua Stern. Recruiting at 1 site in United States. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Joshua Stern · Early Phase 1, Interventional, and Treatment
…and 10 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Kidney Calculi with a site in United States — 42 open to participants now, 58 under way, none of them phase 3. Kidney Calculi · United States.
Among the 193 studies in Kidney Calculi with a site in United States, this one is the 116th largest by planned enrollment of the 165 interventional ones that give a count, is one of 13 that started in 2024, is one of 8 in phase 1, reaches primary completion later than 38 of the 57 other live ones, and was the 138th registered.
510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.
Browse Kidney Calculi studies →42 of the 193 studies in Kidney Calculi with a site in United States are open now. Recruiting first, the newest first:
Calyxo, Inc. · Sites in United States
Ages 18+
YolTech Therapeutics Co., Ltd · Sites in United States
Ages 6+
Children's Hospital of Philadelphia · Sites in United States
Ages 6+
Ohio State University · Sites in United States
Ages 18+
Calyxo, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 23 · Phase 3 9 · Phase 4 13
First in 1998; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 86 across 392 interventional studies indexed under Kidney Calculi.
Median enrollment 47 across the 165 interventional studies, 122 across the 28 observational. Of the 116 that completed or were terminated, 51 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 193 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Joshua Stern as lead sponsor.
Joshua Stern has 1 study filed under Kidney Calculi — fewer than ten, so there is no comparison to draw.
17 of the studies in Kidney Calculi with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07296835University of Kansas Medical CenterSurgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope | 2026-11 |
| NCT04651088University of Texas Southwestern Medical CenterComparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet | 2026-12 |
| NCT05993546The Cleveland ClinicRandomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis | 2026-12 |
| NCT04333745University of Alabama at BirminghamInfluence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers | 2026-12-01 |
| NCT04603898University of Alabama at BirminghamOxalate Formation From Ascorbic Acid | 2026-12-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 193 studies in Kidney Calculi with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open-label pilot study evaluates whether oral microbial transplant therapy can change urine factors associated with recurrent calcium-oxalate kidney stones. Adults with high urine calcium or high urine oxalate will receive antibiotic pretreatment followed by microbial capsules. Changes in 24-hour urine calcium and oxalate and treatment safety will be assessed.
Participants with recurrent calcium-oxalate stones are assigned to a hyperoxaluric or hypercalciuric cohort based on baseline 24-hour urine results. All participants receive vancomycin 500 mg twice daily and neomycin 1,000 mg twice daily for 3 days. Forty-eight to 72 hours later, they take 2 microbial transplant therapy capsules daily for 7 days. Urine and stool samples are collected at baseline, after antibiotics, and during follow-up. Participants serve as their own controls. Follow-up includes weekly contacts through Week 5, telephone/record review at Months 2-6, and record review at Months 9 and 12
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with urinary oxalate \>40 mg/day and \<80 mg/day receive antibiotic pretreatment followed by MTT, 2 capsules daily for 7 days.
Drug: Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101) · Drug: Vancomycin and neomycin antibiotic pretreatment
Participants with urinary calcium \>225 mg/day receive antibiotic pretreatment followed by MTT, 2 capsules daily for 7 days
Drug: Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101) · Drug: Vancomycin and neomycin antibiotic pretreatment
Two capsules orally once daily for 7 days, beginning 48-72 hours after completion of antibiotic pretreatment.
Also known as: fecal transplant
Vancomycin 500 mg orally twice daily and neomycin 1,000 mg orally twice daily for 3 days before MTT.
Change in 24-hour urinary oxalate concentration from baseline
Within-participant change in urinary oxalate concentration measured in 24-hour urine collections.
Time frame: Baseline to Weeks 1, 3, and 5
Change in 24-hour urinary calcium concentration from baseline
Within-participant change in urinary calcium concentration measured in 24-hour urine collections.
Time frame: Baseline to weeks 1, 3, and 5
Proportion of participants with an adverse event
Safety assessed as the proportion of participants experiencing an adverse event through the specified follow-up period.
Time frame: Through Day 30 (+/- 3 days) after MTT
Metagenomic changes in participant microbiota before and after MTT
Changes in stool microbiota measured by metagenomic analysis.
Time frame: Baseline/pre-intervention through Week 5
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2027, 38 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2026 → Dec 2027 and completion Mar 2027 → Mar 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
…and 10 more changes, on the record history on ClinicalTrials.gov ↗
…and 10 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.